What is the recommended management of clinically significant anxiety in an older adult with frontotemporal dementia?

Management of Anxiety in Frontotemporal Dementia

In frontotemporal dementia (FTD), what appears as "anxiety" is typically agitation or restlessness stemming from the underlying neurodegenerative process rather than true anxiety disorder, and should NOT be treated with anxiolytics. 1, 2

Critical Diagnostic Distinction

The emotional distress that characterizes primary anxiety disorders is usually absent in FTD patients, who instead present with prominent emotional blunting and lower than expected subjective distress symptoms. 1 This is a fundamental difference that changes the entire treatment approach:

• Restlessness or agitation in FTD should not be misinterpreted as anxiety that would justify anxiolytic therapy; the underlying neurobiology differs fundamentally from primary anxiety disorders 2
• FTD patients show marked lack of concern and insight, distinguishing them from most psychiatric disorders (except severe psychosis/mania) 1, 2
• Approximately 50% of individuals with FTD receive an initial psychiatric misdiagnosis, with diagnostic delays averaging 5-6 years 2

First-Line Treatment Approach

Selective serotonin reuptake inhibitors (SSRIs) are the preferred first-line pharmacologic treatment for behavioral symptoms in FTD, including agitation that may be mistaken for anxiety. 2, 3, 4, 5

SSRI Implementation:

• Start with low doses of citalopram or sertraline and gradually titrate upward to therapeutic range over several weeks 6
• SSRIs are preferred due to minimal anticholinergic effects and better safety profile in elderly patients 6
• If no clinically meaningful improvement occurs after four weeks of adequate dosing, taper and discontinue the medication 2
• SSRIs may reduce disinhibition, repetitive behaviors, and hyperorality that can manifest as apparent distress 4, 5

Medications to Avoid

Benzodiazepines and traditional anxiolytics have no role in FTD management and should be avoided entirely. 6, 2

• Benzodiazepines worsen cognition, increase fall risk, and can cause paradoxical agitation 6
• Long-acting benzodiazepines are particularly dangerous due to accumulation and increased adverse effects 6
• Anticholinergic medications worsen cognition and increase confusion 6

Antipsychotics should be avoided except as a carefully monitored, short-term last resort for severe agitation, due to increased risk of death from cardiac toxicities. 2, 3

• When antipsychotics are used, extreme caution is required due to heightened risks of falls, stroke, and mortality 2
• Small doses of atypical antipsychotics may occasionally help decrease agitation and verbal outbursts, but only after other options have failed 4

Cholinesterase inhibitors and memantine should not be used in FTD, as they have not demonstrated consistent benefit in this population. 2, 3, 5

Valproate (Depakote) has no role in managing behavioral symptoms of FTD; the risk-benefit ratio is unacceptable given lack of efficacy and significant harm. 2

Non-Pharmacological Interventions (Primary Approach)

Behavioral and environmental modifications should be the primary treatment approach before considering any medication. 1, 6

Specific Interventions:

• Apply the "three R's" technique (Reassure, Reconsider, Redirect) and modify the environment to reduce triggers 6
• Provide structured, tailored activities aligned with the patient's current capabilities and previous interests 6
• Implement caregiver education and support as a cornerstone of management 1, 4, 5
• Consider physical exercise programs including aerobic, resistance, and balance exercises, which benefit both dementia and behavioral symptoms 6

Assessment Requirements

Do not rely on patient self-report for symptom assessment in FTD due to impaired insight; obtain collateral information from caregivers. 1, 2

• A caregiver-based history is essential given the impaired insight almost always present in FTD 1
• Establish a clear timeline of symptoms including age at onset, predominant early symptoms, and progression over time 1
• Use behavioral clinical scales such as the Frontal Behavioral Inventory (FBI) or Stereotypy Rating Inventory (SRI) for systematic assessment 1
• The Neuropsychiatric Inventory (NPI) can evaluate psychiatric symptoms but is not sufficient alone to rule out primary psychiatric disorders 1

Common Pitfalls to Avoid

• Do not dismiss a potential FTD diagnosis because of a positive psychiatric history; psychiatric symptoms can be the initial presentation of FTD 2
• Do not misclassify agitation as anxiety and prescribe inappropriate medications such as SNRIs or benzodiazepines 2
• Do not use standard anxiety screening tools (like GAI or PSWQ-A) designed for primary anxiety disorders, as these are not validated for FTD 1, 6

Monitoring and Follow-Up

• Reassess behavioral symptoms at 4-6 weeks using the same validated screening tools 6
• Monitor for treatment-emergent side effects, particularly cognitive worsening, falls, or behavioral changes 6
• Evaluate caregiver burden and distress as part of ongoing management 6

Genetic Considerations

Consider genetic testing for C9orf72 repeat expansions in all possible or probable FTD cases, especially when prominent psychiatric features are present. 2

• Psychotic symptoms are more common in C9orf72 mutations, including somatic delusions potentially related to altered body schema 1